EP0652011A4 - Prophylaktisches mittel und arzneimittel für virale erkrankungen der atemwege. - Google Patents

Prophylaktisches mittel und arzneimittel für virale erkrankungen der atemwege.

Info

Publication number
EP0652011A4
EP0652011A4 EP93913569A EP93913569A EP0652011A4 EP 0652011 A4 EP0652011 A4 EP 0652011A4 EP 93913569 A EP93913569 A EP 93913569A EP 93913569 A EP93913569 A EP 93913569A EP 0652011 A4 EP0652011 A4 EP 0652011A4
Authority
EP
European Patent Office
Prior art keywords
respiratory tract
virus
viral diseases
agent
against viral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP93913569A
Other languages
English (en)
French (fr)
Other versions
EP0652011A1 (de
Inventor
Hiroshi Kido
Masato Tashiro
Kentaro Sakai
Shozaburo Sekido
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanabe Pharma Corp
Original Assignee
Tokyo Tanabe Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tokyo Tanabe Co Ltd filed Critical Tokyo Tanabe Co Ltd
Publication of EP0652011A1 publication Critical patent/EP0652011A1/de
Publication of EP0652011A4 publication Critical patent/EP0652011A4/de
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/785—Alveolar surfactant peptides; Pulmonary surfactant peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/42—Respiratory system, e.g. lungs, bronchi or lung cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EP93913569A 1992-06-24 1993-06-23 Prophylaktisches mittel und arzneimittel für virale erkrankungen der atemwege. Ceased EP0652011A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP165875/92 1992-06-24
JP16587592A JP3961029B2 (ja) 1992-06-24 1992-06-24 インフルエンザウィルス感染防止剤
PCT/JP1993/000851 WO1994000131A1 (fr) 1992-06-24 1993-06-23 Agent prophylactique et agent curatif contre des maladies virales des voies respiratoires

Publications (2)

Publication Number Publication Date
EP0652011A1 EP0652011A1 (de) 1995-05-10
EP0652011A4 true EP0652011A4 (de) 1996-06-05

Family

ID=15820643

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93913569A Ceased EP0652011A4 (de) 1992-06-24 1993-06-23 Prophylaktisches mittel und arzneimittel für virale erkrankungen der atemwege.

Country Status (6)

Country Link
EP (1) EP0652011A4 (de)
JP (1) JP3961029B2 (de)
KR (1) KR950702122A (de)
AU (1) AU690520B2 (de)
CA (1) CA2138281A1 (de)
WO (1) WO1994000131A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT75660A (en) * 1994-03-23 1997-05-28 Tokyo Tanabe Co Novel remedy for respiratory-tract viral disease
WO1996017872A1 (en) * 1994-12-07 1996-06-13 Tokyo Tanabe Company Limited Intermediate for producing surfactant peptide
CN1194833A (zh) * 1997-10-08 1998-10-07 刘柏宏 肺活素
ATE269101T1 (de) 1999-01-19 2004-07-15 Altana Pharma Ag Rekombinantes sp-a zur behandlung und vorbeugung von pulmonaren infektionen und entzündungen
MXPA04002446A (es) 2001-09-26 2004-07-23 Baxter Int Preparacion de nanoparticulas de tamano de submicras mediante dispersion y remocion de la fase liquida o solvente.
KR20030033266A (ko) * 2001-10-19 2003-05-01 (주)인터루션 사용자의 영상정보 분석을 통한 사이버 비서 시스템 및 그방법
GB0201028D0 (en) * 2002-01-17 2002-03-06 Britannia Pharmaceuticals Ltd Prevention of infectious diseases
EP1531795A4 (de) * 2002-05-02 2011-02-23 Harvard College Formulierungen zur begrenzung der ausbreitung von lungeninfektionen
JP2007520555A (ja) * 2004-02-05 2007-07-26 バクスター・インターナショナル・インコーポレイテッド 自己安定化剤の使用により調製された分散剤
US20050207983A1 (en) 2004-03-05 2005-09-22 Pulmatrix, Inc. Formulations decreasing particle exhalation
JP4843792B2 (ja) * 2004-04-05 2011-12-21 国立大学法人徳島大学 経粘膜及び経皮投与を可能にする抗原薬物ヴィークル、これを用いる粘膜免疫の誘導方法、粘膜ワクチン及びｄｄｓ
EP1930025B1 (de) * 2005-08-05 2013-05-01 The University of Tokushima Antigen-und-arznei-vehikel zur ermöglichung der umstellung von der selektiven produktion eines iga-antikörpers auf die produktion von iga- und igg-antikörpern und transnasaler/ mukosaler impfstoff mit diesem vehikel
CA2718130A1 (en) * 2007-03-29 2008-10-09 National Jewish Health Surfactant lipids, compositions thereof, and uses thereof
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
WO2012030664A1 (en) 2010-08-30 2012-03-08 Pulmatrix, Inc. Dry powder formulations and methods for treating pulmonary diseases
EP4008326A1 (de) 2010-09-29 2022-06-08 Pulmatrix Operating Company, Inc. Einwertige metallkationen-trockenpulver zum inhalieren
PT2621488T (pt) 2010-09-29 2019-02-12 Pulmatrix Operating Co Inc Pós secos catiónicos
US20150136130A1 (en) 2012-02-29 2015-05-21 Pulmatrix, Inc. Inhalable dry powders
KR20150135328A (ko) 2013-04-01 2015-12-02 풀매트릭스 인코퍼레이티드 티오트로피움 건조 분말
KR101658048B1 (ko) 2014-06-25 2016-09-20 한국생명공학연구원 포스파티딜콜린 합성경로 관여 물질을 포함하는 항바이러스용 조성물
WO2023281523A1 (en) * 2021-07-09 2023-01-12 Indian Council Of Medical Research A pharmaceutical composition with a recombinant fragment of human surfactant protein-d for sars-cov-2 infection

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0368823A2 (de) * 1988-10-18 1990-05-16 Kabi Pharmacia AB Biologisch wirksames Lipoprotein und seine Verwendung
WO1991017766A1 (fr) * 1990-05-18 1991-11-28 Tokyo Tanabe Company Limited Remede contre l'asthme

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58183620A (ja) * 1982-04-22 1983-10-26 Teijin Ltd 肺表面活性物質及びその製造方法
JPS58222022A (ja) * 1982-06-21 1983-12-23 Teijin Ltd 合成肺表面活性剤及びそれを有効成分とする呼吸窮迫症候群治療剤
JPS59164724A (ja) * 1983-03-10 1984-09-17 Tokyo Tanabe Co Ltd サ−フアクタント及びそれを含有する呼吸窮迫症候群治療剤
JPS6034905A (ja) * 1983-08-05 1985-02-22 Tokyo Tanabe Co Ltd 肺表面活性物質製剤
JPS6429319A (en) * 1987-07-23 1989-01-31 Toyama Chemical Co Ltd Antiviral agent containing lysolecithin and phospholipid
AU3073789A (en) * 1988-03-31 1989-10-05 Abbott Laboratories Drug delivery using pulmonary surfactant to facilitate absorption
DE3929217A1 (de) * 1989-09-02 1991-03-07 Boehringer Mannheim Gmbh Verwendung von phospholipid-derivaten als antivirale arzneimittel und neue phospholipide

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0368823A2 (de) * 1988-10-18 1990-05-16 Kabi Pharmacia AB Biologisch wirksames Lipoprotein und seine Verwendung
WO1991017766A1 (fr) * 1990-05-18 1991-11-28 Tokyo Tanabe Company Limited Remede contre l'asthme
EP0528034A1 (de) * 1990-05-18 1993-02-24 Tokyo Tanabe Company Limited Asthma heilmittel

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
H. KIDO ET AL.: "PULMONARY SURFACTANT IS A POTENTIAL ENDOGENOUS INHIBITOR OF PROTEOLYTIC ACTIVATION OF SENDAI VIRUS AND INFLUENZA A VIRUS.", FEBS LETTERS, vol. 322, no. 2, AMSTERDAM NL, pages 115 - 119, XP025605839, DOI: doi:10.1016/0014-5793(93)81549-F *
J.F. VAN IWAARDEN ET AL.: "SURFACTANT PROTEIN A IS OPSONIN IN PHAGOCYTOSIS OF HERPES SIMPLEX VIRUS TYPE 1 BY RAT ALVEOLAR MACROPHAGES.", AMERICAN JOURNAL OF PHYSIOLOGY, vol. 261, no. 2, BETHESDA, MD, US, pages L204 - L209, XP000567068 *
See also references of WO9400131A1 *

Also Published As

Publication number Publication date
JP3961029B2 (ja) 2007-08-15
WO1994000131A1 (fr) 1994-01-06
EP0652011A1 (de) 1995-05-10
KR950702122A (ko) 1995-06-19
JPH069428A (ja) 1994-01-18
AU4357393A (en) 1994-01-24
AU690520B2 (en) 1998-04-30
CA2138281A1 (en) 1994-01-06

Similar Documents

Publication Publication Date Title
FI20001231A7 (fi) 2-Deoksi-2,3-didehydro-N-asetyylineuramiinihapon johdannaisia ja niiden analogeja ja niiden käyttö antiviraalisina aineina
TW200509961A (en) Uses of interferons for the treatment of severe acute respiratory syndrome and other viral infections
DE60229677D1 (de) Langwirkende Fusionspeptidinhibitoren gegen HIV-Infektion
UA66744C2 (en) 5,6-dichlorobenzimidazole derivatives, methods for the preparation thereof, pharmaceutical composition and method for treatment of viral infections
TR199903053T2 (xx) Benzimidazol t�revleri.
ATE476983T1 (de) Immunostimulierende polynukleotide sequenzen zur verwendung bei der verhinderung und behandlung von viralen erkrankungen der atemwege
CY1112560T1 (el) Πνευμονικη μεταφορα των αμινογλυκοσιδων
NO20073151L (no) Fremgangsmater og sammensetninger for a behandle hepatitt C virus
BR0111569A (pt) Agentes antivirais de imidazopiridina e imidazopirimidina
NO20020571L (no) Peptider som blokkerer infeksjonsevnen, og fremgangsmåter for anvendelse av disse
WO2004085682A3 (de) Caspase inhibitoren, insbesondere von caspase-3, zur behandlung von influenza
BR9913333A (pt) Inibição e tratamento do vìrus da hepatite b e flavivìrus com helioxatina e seus análogos
GEP20084377B (en) Agent for inhibiting membrane virus reproduction, method for the production thereof, pharmaceutical composition and method for inhibiting viral infections
NO983090L (no) Terapeutiske forbindelser
BR9915025A (pt) Reversão de choque sistêmico induzido por vìrus e insuficiência respiratória por bloqueio da via linfotoxina-beta
NZ505894A (en) Methylenebisbenzaldehyde derivatives, methylidynetrisphenol derivative and pharmaceuticals thereof; useful for treating or preventing pneumovirus infection and associated diseases
TR200102024T2 (tr) Yeni tedavi.
NO20013167D0 (no) Anvendelse av bisfosfonater for forebygging og behandling av infeksjonsprosesser
NO931246L (no) Sammensetninger for behandling av infeksjon og sykdom foraarsaket av hepatites b virus (hbv)
TR199900523T2 (xx) Vir�s k�kenli hastal�klar�n tedavisi i�in farmas�tik bile�imler.
AR036697A1 (es) Metodo para el tratamiento de la infeccion por virus de hepatitis c en pacientes sin respuesta a tratamiento
BG100835A (bg) Ново лекарствено средство за лечение на вирусни инфекции на дихателните пътища
BR9916043A (pt) Composto, uso do mesmo e de seus saisfarmaceuticamente aceitáveis, e, composiçãofarmacêutica para tratamento de infecções deherpes viral em pacientes
EP0988042A4 (de) Eine kombinationstherapie für hiv infektionen
ATE253938T1 (de) Pharmazeutische kombination von antiviralen wirkstoffen

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19950117

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

RHK1 Main classification (correction)

Ipc: A61K 31/685

A4 Supplementary search report drawn up and despatched

Effective date: 19960418

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 19981020

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

RIC1 Information provided on ipc code assigned before grant

Free format text: 6A 61K 35/42 A, 6A 61K 31/685 B, 6A 61K 31/70 B, 6A 61K 38/00 B, 6A 61K 45/08 B

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: TT PHARMACEUTICALS, INC.

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MITSUBISHI-TOKYO PHARMACEUTICALS, INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20000403